Shares of BioTime, Inc. (NYSEAMERICAN:BTX) have been assigned an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.50.

A number of equities analysts have recently weighed in on BTX shares. Oppenheimer started coverage on shares of BioTime in a research note on Tuesday, December 11th. They set an “outperform” rating and a $3.50 price target on the stock. CIBC started coverage on shares of BioTime in a research note on Tuesday, December 11th. They set an “outperform” rating and a $3.50 price target on the stock. Zacks Investment Research raised shares of BioTime from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Thursday, January 3rd. Maxim Group initiated coverage on shares of BioTime in a research note on Thursday, January 24th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Dawson James initiated coverage on shares of BioTime in a research note on Thursday, February 7th. They issued a “buy” rating on the stock.

NYSEAMERICAN:BTX opened at $1.55 on Friday. BioTime has a fifty-two week low of $0.66 and a fifty-two week high of $2.81.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in BioTime by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 1,227,540 shares of the biotechnology company’s stock valued at $1,120,000 after purchasing an additional 37,279 shares in the last quarter. Jane Street Group LLC lifted its holdings in BioTime by 191.8% in the 4th quarter. Jane Street Group LLC now owns 82,630 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 54,312 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in BioTime by 82.9% in the 4th quarter. Two Sigma Advisers LP now owns 154,253 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 69,900 shares in the last quarter. Two Sigma Investments LP lifted its holdings in BioTime by 265.9% in the 4th quarter. Two Sigma Investments LP now owns 529,977 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 385,116 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in BioTime by 1.3% in the 4th quarter. BlackRock Inc. now owns 6,179,281 shares of the biotechnology company’s stock valued at $5,642,000 after purchasing an additional 76,814 shares in the last quarter.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Read More: Book Value Per Share in Stock Trading

Analyst Recommendations for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.